Eli Lilly and Comp. Stock Buy or Sell? LLY Stocks Forecast

Market Capitalization: 321 559 953 000 $
EBITDA: 10 175 800 000 $
Price to Earnings: 49.01
Quarterly Earnings Growth YOY: 0.13
Quarterly Revenue Growth YOY: -0.087
Trailing PE: 49.01
Forward PE: 39.06
Shares Outstanding: 952347000

Eli Lilly and Comp. Stock Buy or Sell? LLY Stocks Analytic Forecasts

March 31, 2023 (20:26)

Eli Lilly and Company (LLY) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the LLY stock market. Experts share their opinions on what to expect from the Eli Lilly and Company stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell Eli Lilly and Comp. stocks.

Eli Lilly and Company Stock Market Experts’ Analysis and Forecasting – Sell or Buy LLY Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Peter F. Way, CFA and is titled

“Eli Lilly: Best-Now Near-Term Price Gains Pharmaceuticals Stock”

is published on March 23 (2023) and has 2 likes. The review predicts Bullish market trend.

It summarize the following theses:

  • 84% of shares held by 3370 “institutional” investors, with over 80% of its $315 Billion market capitalization traded in a year.
  • Not a buy-to-hold because prior forecasts like today’s 8-to-1 wins to losses reached their sell targets in less than two months, often followed by price reductions.
  • An Active Investment strategy employs time productively, not defensively, because compounding gains is the best means of building wealth most assuredly and rapidly when good forecasts are in hand.
  • The specific stock selections identified are from price forecasts of the current competitive moment, not from some idea of historical averages.
  • LLY ranks high now in reward-to-risk tradeoffs (4.3 to 1) from coming-price expectations made by best-informed investing professionals, evidenced by prior similar-to-today forecasts.

The author starts his analytic review with the following:

The primary focus of this article is Ely Lilly and Company (NYSE:LLY).

This author is very popular among the auditory. He has 17888 followers

Peter F. Way, CFA is the contributor of experts community since 2009 and has a great number of published articles – 1223.

One more noteworthy article is written by Khen Elazar under the title

“Eli Lilly Is Still Overvalued But Should Be On Your Watchlist”

on February 17 (2023) and has 1 likes. The expert reflects Neutral trend of the market.

Нis theses make you think about whether to add LLY stocks to your investment portfolio or not, and helps to work out your own Eli Lilly and Comp. stock selling strategies:

  • Eli Lilly and Company is a fast-growing and promising leading pharmaceutical company.
  • Eli Lilly’s shares are expensive now, trading for almost 40 times future earnings.
  • Therefore, Eli Lilly is priced for perfection, and in this volatile market, it is risky. Thus, Eli Lilly and Company shares are a HOLD.

Khen Elazar starts analysis with such words:

Introduction As an investor focusing on dividend growth, I constantly seek new opportunities to invest in assets that generate reliable income. Whenever I find my existing holdings undervalued, I add to them to maximize my returns. Additionally, I take advantage of market volatility by initiating new positions that help diversify my portfolio and boost my dividend income with a lower amount of capital.

The opinion of the author can be considered quite authoritative.
The number of 8516 followers confirms this.
Khen Elazar is the contributor of experts community since 2015. Has already published at least 418 articles.

Another analysis presented by Clinically Sound Investor came out on February 17 (2023). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for LLY stocks. It sounds like

“Eli Lilly: Mounjaro Needs To Catch Up In 2023”

Article has got 1 likes at the moment and forecasting Neutral trend of the market.

Summarizing the information presented in the review concerning the Eli Lilly and Company, the expert says the following:

  • The Eli Lilly and Company diabetes upstart was on fewer formularies than reported.
  • Less coverage meant lower Eli Lilly and Company sales, contributing to a revenue miss in Q4.
  • In oncology, a label expansion could continue the outperformance of Verzenio.

And here, what comes first:

On February 2, Eli Lilly and Company (NYSE:LLY) announced its financial results for the fourth quarter of 2022. The mixed earnings report hasn’t caused share prices to deviate from the general market movement, although there was some initial momentum due to EPS guidance exceeding Wall Street expectations at the time. The company highlighted their top 10 brands, which generated $5.1 billion and 70% of the company’s total Q4 revenues (Figure 1).

Clinically Sound Investor has already 2782 followers, which shows, he is the one who cares for his words.
The contributor of experts community since 2014. Has already 260 analytic reviews published.

The Share Price of Eli Lilly and Company (LLY) for now

What analysts predict: $380.75
52-week high/low: $383.2 / $273.39

50/200 Day Moving Average: $333.13 / $333.95

The average stock price over the previous 50/200 days. For Eli Lilly and Comp. stocks, the 50-day moving average is the resistance level for now. For LLY stocks, the 200-day moving average is the resistance level today.

See the Detailed Predictions for LLY stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

Bright Green Files For U.S. Direct Listing

Buy or Sell BGXX shares? Bright Green Files For U.S. Direct Listing
April 6, 2022
Bright Green Corporation has filed initial information for a direct listing on the Nasdaq Capital Market.

If You Like Johnson & Johnson, You’ll Love These Higher-Yielding SWANs

Buy or Sell JNJ shares? If You Like Johnson & Johnson, You’ll Love These Higher-Yielding SWANs
March 10, 2023
Recession is coming and with it plenty of scary headlines about crashing stock prices and financial doom.